A potential therapy targeting difficult-to-treat immune system disorders such as rheumatoid arthritis will progress to clinical trials next year after securing $20 million in Series A funding.
1 November 2019Search UQ News
A potential therapy targeting difficult-to-treat immune system disorders such as rheumatoid arthritis will progress to clinical trials next year after securing $20 million in Series A funding.
1 November 2019
Privacy & Terms of use | Feedback
Authorised by: Director, Office of Marketing and Communications
ABN: 63 942 912 684
CRICOS
Provider No: 00025B